10/28/2026
Pharma giants invest billions in psychedelics despite hurdles
Psychedelics like MDMA and psilocybin gain traction amid regulatory challenges.
Topic archive
clinical trials
34 stories
10/22/2026
Ibogaine Club Research Group advises FDA on trial safety
The group emphasizes cardiac risk management in ibogaine clinical trials.
10/20/2026
Psychedelics fast-tracked by FDA under Trump order
Executive order allocates $50 million for psychedelic drug development, including ibogaine.
10/19/2026
FDA seeks input on ibogaine trial design, advances psychedelic framework
FDA's request for ibogaine trial input marks a step in psychedelic drug regulation.
10/11/2026
FDA seeks public input on ibogaine trial safety
Ibogaine trials for opioid use disorder face scrutiny over safety.
10/9/2026
FDA seeks input on ibogaine trials amid safety concerns
FDA's request for ibogaine trial proposals highlights cardiac risks and regulatory challenges.
10/9/2026
FDA seeks public input on ibogaine trials
Gabon aims to secure benefits from rising ibogaine demand
10/9/2026
FDA considers ibogaine clinical trials
Potential trials could explore ibogaine's role in treating opioid addiction.
10/9/2026
Ibogaine shows promise for PTSD in veterans, Stanford study finds
A year-long study suggests ibogaine may help veterans with PTSD, but more research is needed.
10/9/2026
Ibogaine clinical trials: design and safety insights
Exploring safety and design in ibogaine trials for opioid use disorder.
10/8/2026
FDA proposes ibogaine trial design, seeks input
FDA outlines early-stage ibogaine trial design, inviting public feedback.
10/7/2026
FDA proposes strict ibogaine trial guidelines
Public input sought on inpatient care and heart monitoring
10/6/2026
DemeRx appoints ibogaine expert Juan Sanchez-Ramos
Sanchez-Ramos joins as DemeRx advances its alcohol use disorder program.
10/6/2026
FDA seeks public input on ibogaine clinical trials
Public comments sought on trial design, dosing, and safety for ibogaine studies.
10/6/2026
FDA seeks public input on ibogaine trial design
Request focuses on safety, dosing, and oversight for early-phase trials.
10/6/2026
FDA outlines framework for ibogaine trials
New FDA notice suggests guidelines for ibogaine clinical research.
10/5/2026
FDA seeks public input on ibogaine research
Agency requests feedback on clinical trial design for ibogaine drug products.
9/23/2026
Psyence BioMed announces ibogaine investment and trial plans
Psyence BioMed to invest $5M in PsyLabs, plans Texas ibogaine trial.
9/23/2026
Psyence and PsyLabs share exchange to boost ibogaine research
Psyence and PsyLabs collaborate to advance ibogaine for opioid use disorder.
9/16/2026
Compass Pathways reports 52-week follow-up on psilocybin trial
Phase 3 trial shows potential benefits for treatment-resistant depression.
9/16/2026
FDA hearing highlights psychedelic drug trial safety
Public feedback sought on psychedelic drugs' therapeutic potential and safety measures.
9/1/2026
Barrow, ASU launch clinical trial for ibogaine in the US
The study aims to explore ibogaine's potential for treating PTSD and addiction.
8/19/2026
Arizona study to explore ibogaine for PTSD, brain injuries
Barrow Neurological Institute to test ibogaine's safety and efficacy in a state-funded trial.
8/19/2026
Trump highlights ibogaine research in executive order
Ibogaine, a psychedelic drug, gains federal attention for treating addiction.
8/10/2026
Barrow Neurological Institute secures $5M for ibogaine brain injury trial
Arizona funds first U.S. ibogaine trial for traumatic brain injuries, starting 2027.
8/10/2026
Ibogaine trials for opioid use disorder get ARPA-H boost
ARPA-H seeks to accelerate ibogaine trials for opioid treatment
8/8/2026
Psyence BioMed focuses on psilocybin and ibogaine supply
The biotech firm aims for vertical integration in psychedelic therapeutics.
8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.
8/5/2026
Barrow Neurological Institute receives $5M for ibogaine study
Grant supports research into ibogaine's effects on neurological disorders.
7/29/2026
Ibogaine research faces representation challenges
Psychedelic trials often exclude marginalized groups, raising questions about equity and efficacy.
7/29/2026
Scottsdale Research Institute submits IND for ibogaine
Ibogaine HCl aims to treat PTSD, TBI, and opioid use disorder.
7/22/2026
Federal agencies advance psychedelic therapy post-Trump order
Trump's 2026 executive order boosts psychedelic research funding and collaboration.
7/16/2026
San Antonio mayor advocates for ibogaine trials
Mayor Gina Ortiz Jones pushes for psychedelic trials to aid veterans.
7/8/2026
Ibogaine trials advance amid complex legal status
Ibogaine remains illegal in the U.S., yet clinical trials are underway.